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Abstract
Background: In China, schistosomiasis japonica is a predominant zoonotic disease, and animal reservoir hosts in
the environment largely sustain infections. The development of transmission-blocking veterinary vaccines is
urgently needed for the prevention and efficient control of schistosomiasis. Heterologous prime-boost strategy is
more effective than traditional vaccination and homologous prime-boost strategies against multiple pathogens
infection. In the present study, to further improve protective efficacy, we immunized mice with three types of
heterologous prime-boost combinations based on our previously constructed vaccines that encode triosphate
isomerase of Schistosoma japonicum, tested the specific immune responses, and evaluated the protective efficacy
through challenge infection in mice.
Methods: DNA vaccine (pcDNA3.1-SjTPI.opt), adenoviral vectored vaccine (rAdV-SjTPI.opt), and recombinant protein
vaccine (rSjTPI) were prepared and three types of heterologous prime-boost combinations, including DNA i.m.
priming-rAdV i.m. boosting, rAdV i.m. priming-rAdV s.c. boosting, and rAdV i.m. priming-rSjTPI boosting strategies,
were carried out. The specific immune responses and protective efficacies were evaluated in BALB/c mice
Results: Results show that different immune profiles and various levels of protective efficacy were elicited by using
different heterologous prime-boost combinations. A synergistic effect was observed using the DNA i.m. priming-
rAdV i.m. boosting strategy; however, its protective efficacy was similar to that of rAdV i.m. immunization.
Conversely, an antagonistic effect was generated by using the rAd i.m. priming-s.c. boosting strategy. However, the
strategy, with rAdV i.m. priming- rSjTPI s.c. boosting, generated the most optimal protective efficacy and worm or
egg reduction rate reaching up to 70% in a mouse model.
Conclusions: A suitable immunization strategy, rAdV i.m. priming-rSjTPI boosting strategy, was developed, which
elicits a high level of protective efficacy against Schistosoma japonicum infection in mice.
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Background
Schistosomiasis is an important neglected tropical
disease caused by trematode flatworms of the genus
Schistosoma [1, 2]. Schistosomiasis transmission has
been reported in 78 countries or regions in Africa, Asia
and Southern America, and it has been estimated that at
least 258.9 million people required preventive treatment
in 2014 [3]. In China, schistosomiasis (caused by S.
japonicum) is the most severe disease in history. Al-
though extensive achievements have been made through
its efficient control in the past several years, schistosom-
iasis remains endemic in the lowland marsh areas or
lake regions of Hunan, Hubei, Jiangxi, Anhui and Jiangsu
provinces and in the mountain areas of Sichuan and
Yunnan provinces [4, 5]. In 2014, it was reported that
there were 115,614 cases of schistosomiasis japonica
distributed in 453 counties and 919,579 cattle raised in
epidemic areas [6].
Praziquantel, an effective chemotherapy drug against
S. japonicum that is relatively safe and of low cost, does
not prevent host reinfection, and repeated chemotherapy
treatment may generate drug resistance or decreased
effectiveness against worms [7–10]. In China, schisto-
somiasis japonica is also a predominant zoonotic disease,
and there are more than 40 animal reservoir hosts in the
environment, including water buffalo, cattle, pigs and
goats, which in turn largely contribute to sustaining the in-
fection [11, 12]. Therefore, development of transmission-
blocking veterinary vaccines is urgently needed for the pre-
vention and efficient control of schistosomiasis in China.
Results from seroepidemiological investigation and
studies of the radiation-attenuated cercariae model have
provided evidence for the feasibility of vaccine develop-
ment against schistosome infection [13, 14]. The World
Health Organization (WHO) proposed that a vaccine
with partial protective efficacy (≥ 50%) could ease host
damage, reduce environmental pollution by eggs, and
decrease overall morbidity [15]. Vaccines against S. japo-
nicum have been studied for several years, and numer-
ous antigen candidates from all life stages have been
tested, including the 23-kDa membrane protein (Sj23),
fatty acid-binding protein (SjFABP), and glutathione-S-
transferase (SjGST). However, the protective efficacy in-
duced by these antigens are not as ideal as expected
[16–19]. Therefore, strategies for the improvement of
protective efficacy should be further investigated for the
development of novel vaccines against S. japonicum
infection.
In recent years, a novel vaccination strategy, heterol-
ogous prime-boost, which uses unmatched vaccine delivery
methods for immunization while using the same antigen,
has been extensively applied in vaccine studies and has
been determined to be more effective than traditional
vaccination strategy of homologous prime-boost strategy
[20]. Different prime-boost formats have been widely used
in vaccine research against malaria, tuberculosis and AIDS,
such as DNA priming-protein boosting and DNA priming-
viral vectored vaccine boosting [21–23]. In our previous
study, we cloned and optimized codon usage of the
gene, triosephosphate isomerase of S. japonicum
(SjTPI) for the first time [24]. Different types of vaccines
were constructed, including DNA vaccine (pcDNA3.1-
SjTPI, pcDNA3.1-SjTPI.opt), recombinant protein vaccine
(rSjTPI), and recombinant adenoviral vaccine (rAdV-
SjTPI.opt), and its protective efficacy was evaluated in a
mouse model by using homologous prime-boost strategy.
The results showed that worm reduction rates did not
stabilize at the 50% level, a value recommended by the
WHO. However, worm reduction rates significantly in-
creased from 26.9 to 36.9% when a DNA priming-protein
boosting strategy was used [17, 24–26].
To further improve protective efficacy, the present
study immunized mice with three different types of
heterologous prime-boost strategies based on our previ-
ously constructed vaccines, tested the specific immune
responses, and evaluated the protective efficacy through
challenge infection of S. japonicum with cercariae.
Methods
Animals and parasites
Six-week-old female BALB/c mice were purchased from
the Shanghai Laboratory Animal Center (SLAC; Shanghai,
China) and used in the vaccination studies. A Chinese
mainland strain of S. japonicum infected Oncomelania
hupensis was provided by Jiangsu Institute of Parasitic
Diseases (Wuxi, China). Cercariae were collected from
infected snails and used in animal challenges.
Vaccine preparation
DNA vaccines (pcDNA3.1-SjTPI.opt) were previously
constructed and purified by using Qiagen Plasmid Mega
Kit (Qiagen, Dusseldorf, Germany) according to the
manufacturer’s instructions. The final plasmid DNAs
were in 0.01 M phosphate buffered solution (PBS) and
verified for immunization by restriction enzyme diges-
tion and DNA sequencing [24]. Recombinant proteins
(rSjTPI) were purified from a prokaryotic expression sys-
tem (pGEX-4T-3 as a vector, previously constructed),
using a GST-tag purification modules (GE Healthcare;
Buckinghamshire, UK), and thrombin (Sigma-Aldrich;
St. Louis, USA) was used to remove the GST-tag [27].
The rSjTPI was diluted with PBS to a final concentration
of 0.1 mg/ml, stored in aliquots at -80 °C and emulsified
with an equal volume of Freund’s incomplete adjuvant
(Sigma-Aldrich; St. Louis, USA) before immunization.
Recombinant adenoviral vectored vaccines (rAdV-
SjTPI.opt) were constructed and purified previously [26],
stored in aliquots at -130 °C until use.
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Animal grouping and immunization
Mice were randomly divided into 11 different groups
(16 mice in each group), which included a blank con-
trol (Control, without any immunization); pcDNA3.1
(DNA vector, immunized intramuscularly, i.m.); Ad
vector (Ad Vector, immunized subcutaneously, s.c.);
Ad vector (Ad Vector, i.m.); pcDNA-SjTPI.opt (DNA
i.m.); rAdV-SjTPI.opt (rAdV s.c.); rAdV-SjTPI.opt
(rAdV i.m.); rSjTPI (rSjTPI s.c.); pcDNA3.1-SjTPI.opt i.m.
priming-rAdV-SjTPI.opt i.m. boosting (DNA i.m. + rAdV
i.m.); rAdV-SjTPI.opt i.m. priming-rAdV-SjTPI.opt s.c.
boosting [rAdV (i.m. + s.c.)]; and rAdV-SjTPI.opt i.m.
priming-rSjTPI s.c. boosting (rAd i.m. + rSjTPI s.c.).
Immunization was performed four times for the heterol-
ogous prime-boost groups (three times for priming and
one for boosting) and three times for the other groups.
The immunization doses for each vaccine were performed
according to our previous studies. Briefly, the doses were
100 μg (DNA plasmids), 100 μg (rSjTPI) and 108 pfu
(rAdV) for each mouse in every immunization [24–26].
Measurement of rSjTPI-specific antibody responses
Serum samples of each mouse were collected from caudal
veins before immunization and challenge. Indirect enzyme
linked immunosorbent assays (ELISAs) were used to
measure rSjTPI-specific antibody responses, including
IgG levels, IgG subclass (IgG1 and IgG2a) levels, IgG
avidity, and IgG titer. rSjTPI (rTPI, purified previously)
was used as the antigen source. To measure IgG, IgG1,
and IgG2a levels, serum samples at a 1:100 dilution were
added into ELISA plates (Nunc) that were coated with
rTPI (0.2 μg/well) and recognized by second antibodies
(HRP-conjugated goat-anti-mouse IgG, IgG1, and IgG2a,
SouthernBiotech; Birmingham, USA) at a 1:5000 dilution.
The optical density (OD) was read at a wavelength of
450 nm with a microplate reader (Antobio; Zhengzhou,
China). To assess IgG avidity, an additional washing step
with 6 M urea in PBST was performed after serum incu-
bation to discard low avidity IgG, and the avidity index
was calculated as the ratio of the OD450 treated and
OD450 untreated, as described elsewhere [28, 29]. To
measure IgG titers, serum samples from each mouse were
examined using multiple dilutions (from 1:50 to
1:638,400) and the IgG titer was determined by comparing
these to the OD450 value of the control (cut-off value ≥
2.1 × the mean OD450 value of the control).
Cytokine measurements
Two days before challenge, four mice from each group
were randomly sacrificed, and cell suspensions were pre-
pared under aseptic conditions by grinding the spleens
and filtering through 200-mesh screens. The splenocytes
from each mouse were cultured in triplicate (cell density:
5 × 105 cells per well) in 96-well plates (Corning; NY,
USA), incubated in RPMI 1640 medium (Hyclone; South
Lagan, USA) supplemented with 10% fetal calf serum
(Gibco; Grand Island, USA), and stimulated with rTPI
(10 μg/ml), ConA (Sigma-Aldrich; St. Louis, USA,
10 μg/ml), or medium alone (mock) at 37 °C with 5%
CO2 for 72 h. The supernatants were collected, and
cytokine levels were measured using a BD Cytometric
Bead Array (CBA) Mouse Th1/Th2/Th17 Cytokine Kit,
according to the manufacturer’s protocols.
Elispot assay
Cell suspensions from each group were prepared and
stimulated as earlier described. The number of IL-4 and
IFN-γ secreting cells were determined using mouse IL-4
and IFN-γ ELISpot kits (R&D; Minneapolis, USA),
according to the manufacturer’s protocols. Spot forming
units (SFU) were counted using the ELISpot Immuno-
Spot S5 Analyzer (C.T.L., Germany) and analyzed using
the C.T.L. ImmunoSpot image software version 5.1. The
results were expressed as SFU for 1 × 106 cells.
Detection of specific antibodies against adenoviruses
Viral particles (VPS) of adenoviruses were determined by
using the OD260 method (1 OD260 = 1.1 × 10
12 VPS/ml)
[30]. In addition, indirect ELISAs were performed to de-
tect adenovirus-specific antibody levels. Adenoviruses
were used as the antigen source. Serum samples from
each group at a 1:100 dilution were added into plates
coated with adenovirus (107 VPS/well) and recognized by
secondary antibodies (HRP-conjugated goat anti-mouse
IgG, SouthernBiotech; Birmingham, USA) at a 1:5000
dilution. ODs were read at a wavelength of 450 nm using
a microplate reader (Antobio; Zhengzhou, China).
Animal challenge and efficacy observation
Two weeks after the last immunization, each mouse was
challenged with 40 ± 1 S. japonicum cercariae by abdom-
inal skin penetration. Forty-two days post-challenge, all
mice were sacrificed and perfused to observe worm bur-
dens. Worm (female worm) reduction rate was calculated
by using the following formula: Reduction rate (%) = [1 -
Average total worm (or female worm) burden in each
group/Average total worm (or female worm) burden in the
control group] × 100. Whole livers from each mouse were
collected, weighted, and digested with 5 ml of 5% potas-
sium hydroxide (KOH) at 37 °C for 72 h. Ten microliters
of the liver digest were loaded onto a glass counting slide
to count the number of eggs (repeated 3 times), and the
number of eggs per gram liver from each mouse was calcu-
lated. Liver egg reduction rates were calculated by using
the following formula: Reduction rate (%) = (1 - Average
number of eggs per gram liver in each group/Average
number of eggs per gram liver in the control group) × 100.
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Histopathological examination of livers
Areas of single egg granuloma in the livers were
observed by using sectioned liver tissues (1–5 cm3)
collected from each mouse. The procedures of section
preparation were according to standard histological
operations, including fixation in 4% formaldehyde, dehy-
dration in alcohol, embedding in paraffin, and staining
with hematoxylin-eosin. Egg granulomas in the liver
were observed and imaged under a light microscope
(Olympus BX51; Tokyo, Japan). Areas of each single egg
granuloma were determined using a computerized image
analysis system (JD801 Version 1.0; Nanjing, China).
Granuloma sizes were expressed as the means of areas
measured in μm2 ± SD.
Statistical analysis
Statistical analysis was performed using the SPSS software
(Version 19.0). One-way ANOVA was used for data com-
parison among different groups, and the paired Student’s
t-test was used to compare any two means. P-values < 0.05
or < 0.01 were considered statistically significant.
Results
Specific immune responses and protective efficacy
induced through DNA i.m. priming-rAdV i.m. boosting
strategy against S. japonicum infection
Compared to the control or vector immunized group,
DNA i.m., rAdV i.m., and DNA i.m. + rAdV i.m.
immunization induced significantly higher IgG (ANOVA,
F(5,42) = 135.76, P < 0.001), IgG1 (ANOVA, F(5,42) = 33.99,
P < 0.001), and IgG2a (ANOVA, F(5,42) = 157.70, P
< 0.001) levels and IgG titers (ANOVA, F(5,42) = 78.33, P
< 0.001), respectively. Levels of IgG and IgG titers induced
by DNA i.m. + rAdV i.m. immunization were signifi-
cantly higher compared to that induced by DNA i.m.
immunization (t-test, t(15) = 15.93, P < 0.001 and, t(15)
= 3.24, P = 0.005), but significantly lower compared to
that induced by rAdV i.m. immunization (t-test, t(15) =
5.52, P = 0.02 and t(15) = 3.98, P = 0.001) (Fig. 1a, b). rAdV
i.m. and DNA i.m. + rAdV i.m. immunization elicited
higher IgG avidity when compared to that induced by
DNA i.m. immunization, and IgG avidity indices were
0.909, 0.823, and 0.597, respectively (t-test, t(15) = 5.89, P
< 0.001 and t(15) = 8.21, P < 0.001) (Fig. 1c). DNA i.m.,
rAdV i.m., and DNA i.m. + rAdV i.m. immunization in-
duced similar IgG2a biased levels, and IgG2a/IgG1 ratios
were 1.47, 1.34, and 1.55, respectively. However, the highest
IgG2a levels were produced by rAdV i.m. immunization
(ANOVA, F(2,21) = 66.22, P < 0.001) (Fig. 1d).
CBA and ELISpot analysis showed that splenocytes
from DNA i.m., rAdV i.m., and DNA i.m. + rAdV i.m.
immunized groups produced higher levels of Th1 cyto-
kines (IL-2, IFN-γ, and TNF) than those immunized with
a vector (ANOVA, F(5,42) = 7.17, P < 0.001; F(5,42) = 9.27,
P < 0.001; F(5,42) = 16.18, P < 0.001, respectively). Cytokine
levels (IL-2, IFN-γ, and TNF) induced by DNA i.m. +
rAdV i.m. immunization were higher than those
induced by DNA i.m. immunization (t-test, t(15) =
2.60, P = 0.02 for IL-2 in DNA i.m. + rAdV i.m. vs
DNA i.m.; t(15) = 4.07, P = 0.001 for IFN-γ in DNA
i.m. + rAdV i.m. vs DNA i.m.; t(15) = 2.73, P = 0.03 for
TNF in DNA i.m. + rAdV i.m. vs DNA i.m.), but
lower than that induced by rAdV i.m. immunization
(t-test, t(15) = 4.87, P < 0.001 for IL-2 in DNA i.m. +
rAdV i.m. vs rAdV i.m.; t(15) = 2.95, P = 0.02 for IFN-γ
in DNA i.m. + rAdV i.m. vs rAdV i.m.; t(15) = 5.27, P
< 0.001 for TNF in DNA i.m. + rAdV i.m. vs rAdV
i.m.). However, no significant differences in the
amount of IFN-γ secreting cells between rAdV i.m.
and DNA i.m. + rAdV i.m. immunizations were ob-
served (t-test, t(19) = 1.73, P = 0.10) (Fig. 1e-h). Various
types of Th2 (IL-4, IL-6, and IL-10) and Th17 (IL-
17A) cytokines were detected at low levels (Additional
file 1: Figure S1).
The results of protective efficacy are shown in Fig. 5
and Table 1. Compared to the control and vector
groups, DNA i.m., rAdV i.m., and DNA i.m. + rAdV i.m.
immunizations produced lower numbers of adult worms,
female worms, eggs in the liver (ANOVA, F(5,64) = 22.57,
P < 0.001; F(5,64) = 32.87, P < 0.001; F(5,64) = 29.35, P <
0.001, respectively, see Table 1), and smaller areas of
single-egg granuloma in the liver (ANOVA, F(5,64) = 39.25,
P < 0.001, see Fig. 5). DNA i.m. + rAdV i.m. immunization
produced lower numbers of adult worms, female worms,
eggs in the liver, and smaller areas of single-egg granuloma
in the liver compared to that produced by DNA i.m.
immunization (t-test, t(22) = 6.57, P < 0.001; t(22) = 3.68, P
= 0.001; t(22) = 3.57, P = 0.002; t(22) = 8.29, P < 0.001, re-
spectively). However, no statistically significant differences
in protective efficacies between DNA i.m. + rAdV i.m. and
rAdV i.m. immunizations were observed (t-test, t(22) =
2.02, P = 0.055; t(22) = 1.72, P = 0.10; t(22) = 1.57, P = 0.15;
t(22) = 1.14, P = 0.31, respectively).
Specific immune responses and protective efficacy
induced by rAdV i.m. priming-rAdV s.c. boosting strategy
against S. japonicum infection
Compared to the control or vector immunized group,
rAdV s.c., rAdV i.m., and rAdV (i.m. + s.c.)
immunization induced significantly higher IgG, IgG1,
and IgG2a levels and IgG titers, respectively (ANOVA,
F(5,42) = 237.76, P < 0.001; F(5,42) = 99.21, P < 0.001;
F(5,42) = 109.38, P < 0.001; and F(5,42) = 119.36, P < 0.001,
respectively). The IgG and IgG titers induced by rAdV
(i.m. + s.c.) immunization were significantly elevated
compared to that induced by rAdV s.c. immunization
(t-test, t(15) = 2.61, P = 0.02 and t-test, t(15) = 13.14, P <
0.001), but IgG titers were significantly lower to that
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induced by rAdV i.m. immunization (t-test, t(15) = 18.03, P
< 0.001) (Fig. 2a, b). rAdV i.m. and rAdV (i.m. + s.c.) im-
munizations elicited higher IgG avidity compared to that
induced by rAdV s.c. immunization, and IgG avidity indi-
ces were 0.909, 0.903, and 0.480, respectively (see Fig. 2c).
rAdV s.c. and rAdV (i.m. + s.c.) immunization induced
similar IgG1 biased levels, and the IgG2a/IgG1 ratio was
1.34 and 0.74, respectively. However, the high-
est IgG1 levels were produced by rAdV s.c. immunization
(ANOVA, F(2,21) =4.71, P = 0.03, Fig. 2d).
CBA and ELISpot analysis showed that splenocytes
from rAdV s.c., rAdV i.m., and rAdV (i.m. + s.c.) immu-
nized groups produced higher levels of cytokines (IL-2,
IFN-γ, TNF, IL-6, IL-10, and IL-17A) or number of IL-4/
IFN-γ secreting cells than that immunized with a vector
(ANOVA, F(5,42) = 21.17, P < 0.001; F(5,42) = 9.82, P <
0.001; F(5,42) = 18.12, P < 0.001; F(5,42) = 17.07, P < 0.001;
F(5,42) = 4.37, P = 0.005; F(5,42) = 9.77, P < 0.001; F(5,54) =
6.18, P < 0.001, respectively). Th2-biased cytokine
expression profiles were produced through rAdV s.c.
immunization, whereas rAdV i.m. immunization gener-
ated Th1-biased cytokine expression profiles. CBA
analysis indicated that Th1 type cytokine (IL-2, IFN-γ,
and TNF) levels produced by rAdV (i.m. + s.c.)
immunization were lower than that induced by rAdV
i.m. immunization (t-test, t(15) = 2.29, P = 0.03; t(15) =
2.61, P = 0.02; t(15) = 4.07, P = 0.001, respectively), and
Th2/17 type cytokine (IL-6, IL-10, and IL-17A) levels
were also lower than that induced by rAdV s.c.
immunization (t-test, t(15) = 3.73, P = 0.002; t(15) = 3.29,
P = 0.005; t(15) = 2.95, P = 0.01, respectively) (Fig. 2e-j).
No IL-4 was detected by CBA (data not shown).
Fig. 1 rSjTPI-specific immune responses induced by a DNA vector (i.m.), Ad vector (i.m.), DNA (i.m.), rAdV (i.m.), DNA (i.m.) + rAdV (i.m.) immunized
groups and the control group. a IgG responses. b IgG titers. c IgG avidity. d IgG1 and IgG2a responses. e IL-2 levels. f IFN-γ levels. g TNF levels.
h Spot counts of IL-4 and number of IFN-γ secreting cells. Each bar represents the mean ± standard deviation (SD). *P < 0.05; **P < 0.01
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Table 1 Summary of the protective efficacies of the different immunization groups
Group No. of
mice
Adult worms Female worms Eggs in the liver
No. of worms Reduction (%) No. of worms Reduction (%) No. of eggs Reduction (%)
Control 11 28 .33 ± 2.55 – 13.67 ± 1.50 – 114,434 ± 17,170 –
DNA vector (i.m.) 12 27.13 ± 6.42 4.26 13.25 ± 3.15 3.05 107,435 ± 25,289 6.12
Ad vector (i.m.) 12 26.50 ± 3.16 6.47 13.00 ± 1.77 4.88 106,826 ± 18,808 6.65
Ad vector (s.c.) 11 26.27 ± 2.72 7.27 12.73 ± 1.35 6.87 109,061 ± 25,571 4.70
DNA (i.m.) 12 19 .22 ± 1.64a 32.16 9.33 ± 1.00a 31.71 72,947 ± 26,998a 36.25
rAdV (i.m.) 12 14.00 ± 4.84a,b 50.59 6.18 ± 1.94a,b 54.77 54,883 ± 26,892a,b 52.04
rAdV (s.c.) 11 18.00 ± 5.24a 36.47 8.63 ± 2.83a 36.89 67,077 ± 21,277a 41.38
rSjTPI (s.c.) 12 20.78 ± 4.52a 26.67 10.22 ± 2.39a 25.20 70,993 ± 28,772a 37.96
DNA (i.m.) + rAdV (i.m.) 11 15.55 ± 4.61a,c 45.13 6.82 ± 2.71a,c 50.11 51,991 ± 11,395a,c 54.57
rAdV (i.m. + s.c.) 12 15.75 ± 6.09a,d 44.41 7.58 ± 2.81a,d 44.51 49,095 ± 14,323a,d 57.10
rAdV (i.m.) + rSjTPI (s.c.) 12 7.91 ± 2.47a,e 72.09 3.73 ± 1.19a,e 72.73 31,891 ± 17,776a,e 72.13
aStatistically significant differences (P < 0.01), compared to the control or vector control group
bStatistically significant differences (P < 0.01), compared to the DNA (i.m.), rAdV (s.c.), or rSjTPI (s.c.) group
cStatistically significant difference (P < 0.01), compared to the DNA (i.m.) group
dStatistically significant difference (P < 0.05), compared to the rAdV (s.c.) group
eStatistically significant differences (P < 0.01), compared to each group
Fig. 2 rSjTPI-specific immune responses induced by Ad vector (s.c.), Ad vector (i.m.), rAdV (s.c.), rAdV (i.m.), and rAdV (i.m. + s.c.) immunized groups and the
control group. a IgG responses. b IgG titers. c IgG avidity. d IgG1 and IgG2a responses. e IL-2 levels. f IFN-γ levels. g TNF levels. h IL-6 levels. i IL-10 levels.
j IL-17A levels. k Spot counts of IL-4 and number of IFN-γ secreting cells. Each bar represents the mean ± standard deviation (SD). *P< 0.05; **P< 0.01
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ELISpot analysis showed that the number of IL-4 se-
creting cells induced by rAdV (i.m. + s.c.) was lower
than that induced by rAdV s.c. (t-test, t(19) = 3.58, P =
0.002), whereas the amount of IFN-γ secreting cells
did not significantly differ from that induced by rAdV
i.m. immunization (Fig. 2k).
The results of the assessment of protective efficacy
are shown in Fig. 5 and Table 1. Compared to the con-
trol and vector groups, rAdV s.c., rAdV i.m., and rAdV
(i.m. + s.c.) immunizations produced lower numbers of
adult worms, female worms, eggs in the liver (ANOVA,
F(5,63) = 52.31, P < 0.001; F(5,63) = 33.28, P < 0.001; F(5, 63)
= 29.76, P < 0.001, respectively, see Table 1), and smaller
areas of single-egg granulomas in the liver (ANOVA,
F(5,63) = 30.11, P < 0.001, Fig. 5). rAdV (i.m. + s.c.)
immunization produced a lower number of adult
worms, female worms, eggs in the liver, and smaller
areas of single-egg granulomas in the liver compared
to that produced by rAdV s.c. immunization(t-test,
t(22) = 2.34, P = 0.04; t(22) = 2.81, P = 0.01; t(22) = 2.27, P =
0.04; t(22) = 2.77, P = 0.015, respectively). However, no sta-
tistically significant differences in protective parameters
between rAdV (i.m. + s.c.) and rAdV i.m. immunizations
were observed.
Specific immune responses and protective efficacy
induced by rAdV i.m. priming-rSjTPI s.c. boosting strategy
against S. japonicum infection
Compared to the control group, rAdV i.m., rSjTPI s.c., and
rAdV i.m. + rSjTPI s.c. immunizations elicited higher IgG
levels and IgG titers (ANOVA, F(4,35) = 137.21, P < 0.001;
F(4,35) = 39.31, P < 0.001, respectively), whereas rSjTPI s.c.
and rAdV i.m. + rSjTPI s.c. immunizations elicited higher
IgG responses (including IgG levels and IgG titers) than that
using rAdV i.m. immunization (t-test, t(15) = 2.21, P= 0.04
for IgG in rSjTPI s.c. vs rAdV i.m.; t(15) = 2.60, P = 0.02 for
IgG titers in rSjTPI s.c. vs rAdV i.m.; t(15) = 2.37, P < 0.034
for IgG in rAdV i.m. + rSjTPI s.c. vs rAdV i.m.; t(15)
= 2.92, P = 0.01 for IgG titers in rAdV i.m. + rSjTPI
s.c. vs rAdV i.m., respectively) (Fig. 3a, b). The IgG
avidity indices of the three groups were 0.973, 0.809,
and 0.983, respectively (Fig. 3c). The three different
immunization types elicited various levels of IgG sub-
classes (Fig. 3d). rSjTPI s.c. immunization induced a
higher IgG1 level, with a IgG2a/IgG1 ratio of 0.61(t-
test, t(15) = 5.01, P < 0.001). rAdV i.m. immunization
induced a higher IgG2a level, with a IgG2a/IgG1 ratio
of 1.31(t-test, t(15) = 2.95, P = 0.01). The IgG1 and
IgG2a levels were simultaneously elicited by rAdV
i.m. + rSjTPI s.c. immunization, with an IgG2a/IgG1
ratio of 1.08. Furthermore, rAdV i.m. priming-rSjTPI
s.c. boosting immunization elicited the highest spe-
cific IgG2a levels (ANOVA, F(2,21) = 37.21, P < 0.001).
CBA and ELISpot analyses showed that splenocytes
from rSjTPI s.c., rAdV i.m. and rAdV i.m. + rSjTPI s.c.
immunized groups produced higher levels of cytokines
(IL-2, IFN-γ, TNF, IL-6, IL-10, and IL-17A) or numbers
of IL-4/IFN-γ secreting cells than that immunized with a
vector or the control group (ANOVA, F(4,35) = 41.25, P <
0.001; F(4,35) = 10.07, P < 0.001; F(4,35) = 28.34, P < 0.001;
F(4,35) = 25.19, P < 0.001; F(4,35) = 14.24, P < 0.005; F(4,35) =
31.17, P < 0.001; F(4,45) = 16.46, P < 0.001, respectively)
(Fig. 3e-k). Splenocytes from mice that underwent
rAdV i.m. immunization produced higher levels of
Th1 cytokines (IL-2, TNF, and IFN-γ), whereas rSjTPI
s.c. immunization induced higher levels of Th2 (IL-4,
IL-6, and IL-10) and Th17 (IL-17A) cytokines. Fur-
thermore, the IFN-γ, IL-6, IL-10 levels and the num-
ber of IFN-γ secreting cells elicited by rAdV i.m. +
rSjTPI s.c. immunization were higher than those gen-
erated using rAdV i.m.(t-test, t(15) = 4.07, P = 0.001;
t(15) = 8.28, P < 0.001; t(15) = 3.29, P = 0.005; t(19) = 3.58,
P = 0.002, respectively), or rSjTPI s.c. immuniza-
tions(t-test, t(15) = 14.11, P < 0.001; t(15) = 3.28, P =
0.005; t(15) = 4.05, P = 0.001; t(19) = 13.18, P < 0.001, re-
spectively), and the IL-17A levels in the rAdV i.m. +
rSjTPI s.c. immunization group were higher than that
in the rAdV i.m. group but lower than that in the
rSjTPI s.c. group(t-test, t(15) = 19.22, P < 0.001; t(15) =
3.68, P = 0.002, respectively). No IL-4 was detected by
CBA (data not shown).
Figure 5 and Table 1 show the protective efficacy of
various immunization groups. Compared to the con-
trol group and the Ad vector i.m. immunization
group, rSjTPI s.c., rAdV i.m. and rAdV i.m. + rSjTPI
s.c. immunizations resulted in lower numbers of adult
worm, female worms, eggs in the liver (ANOVA, F(4,54) =
11.37, P < 0.001; F(4,54) = 23.57, P < 0.001; F(4,54) = 26.19, P
< 0.001, respectively, see Table 1), and smaller areas of sin-
gle-egg granuloma in the liver (ANOVA, F(4,54) =
10.05, P < 0.001, Fig. 5). rAdV i.m. immunization pro-
duced a lower number of adult worms, female worms,
eggs in the liver, and smaller areas of single-egg
granuloma in the liver compared to that produced by
rSjTPI s.c. immunization (t-test, t(23) = 3.77, P = 0.001;
t(23) = 4.21, P < 0.001; t(23) = 3.49, P = 0.002; t(23) = 8.58,
P < 0.001, respectively). However, rAdV i.m. + rSjTPI
s.c. immunization produced the lowest number of
adult worms, female worms, eggs in the liver and
smallest areas of single-egg granulomas in the liver
compared to that induced in the other groups (t-test,
t(23) = 5.77, P < 0.001; t(23) = 4.29, P < 0.001; t(23) = 5.89,
P < 0.001; t(23) = 8.58, P < 0.001, in rAdV i.m. + rSjTPI
s.c. vs rAdV i.m., respectively; t-test, t(23) = 7.72, P < 0.001;
t(23) = 6.11, P < 0.001; t(23) = 8.19, P < 0.001; t(23) = 7.31, P <
0.001, in rAdV i.m. + rSjTPI s.c. vs rSjTPI s.c.,
respectively).
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Comparison of immune responses and protective efficacy
induced by three heterologous prime-boost strategies
The specific immune responses induced by three
heterologous prime-boost strategies are summarized
in Fig. 4. The high IgG levels and IgG avidity were
elicited by these strategies (Fig. 4a, c), although the
IgG titers and the IgG subclasses differed (Fig. 4b, d).
The rAdV i.m. priming-rSjTPI s.c. boosting strategy
produced the highest IgG titers, whereas the DNA
i.m. priming-rAdV s.c. boosting strategy produced the
lowest (ANOVA, F(2,22) = 11.27, P < 0.001) (Fig. 4b). A
higher IgG2a level was elicited by DNA i.m. + rAdV
i.m. immunization (t-test, t(15) = 3.29, P = 0.005),
whereas, a higher IgG1 level was elicited by rAdV
(i.m. + s.c.) immunization (t-test, t(15) = 2.61, P = 0.02).
The IgG1 and IgG2a levels were simultaneously elic-
ited in the rAdV i.m. + rSjTPI s.c. immunization
group (Fig. 4d).
CBA and ELISpot analyses showed that rAdV i.m. +
rSjTPI s.c. immunization produced the highest cytokine
levels (IFN-γ, TNF, IL-6, IL-10, and IL-17A) and number
of IFN-γ secreting cells (ANOVA, F(2,22) = 9.72, P < 0.001;
F(2,22) = 8.27, P < 0.001; F(2,22) = 11.25, P < 0.001; F(2,22) =
18.01, P < 0.001; F(2,22) = 19.38, P < 0.001; F(2,27) = 22.01, P
< 0.001, respectively), and no significant differences in IL-2
levels between rAdV (i.m. + s.c.) and rAdV i.m. + rSjTPI
s.c. groups were observed (t-test, t(15) = 1.75, P = 0.10).
rAdV (i.m. + s.c.) immunization induced higher cytokine
levels (IL-2, TNF, IL-6, IL-10, and IL-17A) and numbers of
IL-4 secreting cells than that in the DNA i.m. + rAdV i.m.
group (t-test, t(15) = 3.74, P = 0.002; t(15) = 5.35, P < 0.001;
t(15) = 6.31, P < 0.001; t(15) = 5.89, P < 0.001; t(19) = 2.54, P =
0.02, respectively). However, no significant differences in
IFN-γ levels and number of IFN-γ secreting cells between
these two groups were observed (t-test, t(15) = 0.87, P =
0.40; t(19) = 1.73, P = 0.10, respectively Fig. 4e-k).
Fig. 3 rSjTPI-specific immune responses induced by an Ad vector (i.m.), rSjTPI (s.c.), rAdV (i.m.), and rAdV (i.m.) + rSjTPI (s.c.) immunized groups and
the control group. a IgG responses. b IgG titers. c IgG avidity. d IgG1 and IgG2a responses. e IL-2 levels. f IFN-γ levels. g TNF levels. h IL-6 levels.
i IL-10 levels. j IL-17A levels. k Spot counts of IL-4 and number of IFN-γ secreting cells. Each bar represents the mean ± standard deviation (SD).
*P < 0.05; **P < 0.01
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rAdV i.m. + rSjTPI s.c. immunization produced the
lowest number of adult worms, female worms, eggs in
liver, and smallest areas of single-egg granulomas in the
liver compared to that induced in the other two groups
(ANOVA, F(2, 32) = 8.51, P < 0.001; F(2,32) = 6.61, P <
0.001; F(2,32) = 10.09, P < 0.001; F(2,32) = 8.91, P < 0.001,
respectively, Fig. 5 and Table 1). In addition, no sig-
nificant differences in protective parameters between
the DNA i.m. + rAdV i.m. and rAdV (i.m. + s.c.)
groups were observed (t-test, t(22) = 0.86, P = 0.40; t(22) =
1.31, P = 0.20; t(22) = 1.97, P = 0.06; t(22) = 1.52, P = 0.15,
respectively).
Specific IgG levels against adenoviruses as induced by
different groups
The specific IgG levels against adenoviruses are shown
in Fig. 6. Compared to the control group, Ad vector i.m.,
Ad vector s.c., rAdV i.m., rAdV s.c., rAdV (i.m. + s.c.),
and rAdV i.m. + rSjTPI s.c. immunization elicited higher
IgG levels against adenoviruses (ANOVA, F(10,77) = 8.32,
P <0.001). On the other hand, DNA vector i.m., DNA
i.m., rSjTPI s.c., and DNA i.m. + rAdV i.m.
immunization did not elicit specific IgG levels against
adenoviruses. Adenoviruses (Ad vector or rAdV)
immunized intramuscularly elicited higher specific
IgG levels than that induced by subcutaneous
immunization (t-test, t(15) = 3.29, P = 0.005 for IgG in
rAdV i.m. vs rAdV s.c.; t(15) = 2.61, P = 0.02 for IgG in
Ad Vector i.m. vs Ad Vector s.c.). Furthermore, rAdV
(i.m. + s.c.) immunization elicited the highest adeno-
virus specific IgG levels (t-test, t(15) = 5.31, P < 0.001
for IgG in rAdV i.m. + rAdV s.c. vs Ad Vector i.m.;
t(15) = 7.42, P < 0.001 for IgG in rAdV i.m. + rAdV
s.c. vs rAdV i.m.; t(15) = 8.51, P < 0.001 for IgG in
rAdV i.m. + rAdV s.c. vs rAdV s.c.; t(15) = 7.62, P <
0.001 for IgG in rAdV i.m. + rAdV s.c. vs rAdV i.m. +
rSjTPI s.c.).
Fig. 4 rSjTPI-specific immune responses induced by DNA (i.m.) + rAdV(i.m.), rAdV (i.m. + s.c.), and rAdV (i.m.) + rSjTPI (s.c.) immunized groups. a IgG
responses. b IgG titers. c IgG avidity. d IgG1 and IgG2a responses. e IL-2 levels. f IFN-γ levels. g TNF levels. h IL-6 levels. i IL-10 levels. j IL-17A
levels. k Spot counts of IL-4 and number of IFN-γ secreting cells. Each bar represents the mean ± standard deviation (SD). *P < 0.05; **P < 0.01
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Discussion
We evaluated specific immune responses and protective
efficacy against S. japonicum in mice using three types
of heterologous prime-boost combinations, including
DNA i.m. priming-rAdV i.m. boosting, rAdV i.m.
priming-rAdV s.c. boosting, and rAdV i.m. priming-
rSjTPI boosting strategies. The results of the present
study showed that various heterologous prime-boost
combinations elicit different immune profiles, and different
levels of protective efficacy were generated accordingly.
However, the strategy, priming with rAdV intramuscularly,
and boosting with rSjTPI subcutaneously, generated the
optimal protective efficacy and the worm or egg reduction
rate reaching up to 70% in a mouse model.
Previous studies have clearly shown that heterol-
ogous prime-boost vaccination elevates protective effi-
cacy [20–23]. However, its underlying mechanism has
not been clearly elucidated. Different vaccine vectors
or delivery systems may deliver and present protective
antigens in their own way, and this may stimulate the
host immune systems to generate antibodies with
higher avidity, a broad spectrum of specific immune
responses, and the circumvention of anti-vector ef-
fects [31, 32]. Furthermore, previous studies have
shown that a high level of specific Th1 (IFN-γ and
IgG2a) responses is associated with a high degree of
protection against S. japonicum infection in animal
models [33, 34]. However, specific Th2 responses may
also contribute to protection [35]. In our previous
studies, a series of vaccines based on triosephosphate
isomerase of S. japonicum (SjTPI) were constructed,
including a DNA vaccine (pcDNA3.1-SjTPI.opt), a protein
vaccine (rSjTPI), and an adenoviral vectored vaccine
(rAdV-SjTPI.opt). Animal experiments have shown that
DNA and adenoviral vectored vaccines elicit a specific Th1-
biased immune response when immunized intramuscularly,
whereas, protein and adenoviral vectored vaccines elicit a
specific Th2-biased immune response when immunized
subcutaneously [19, 20, 25, 26]. To obtain a vaccination
Fig. 5 The single-egg granuloma responses in the liver induced by each immunization strategy. a Representative granuloma of each group induced
by a single egg in liver (magnification factor 10 × 10; Scale-bars: 100 μm). b Areas of the single-egg granuloma in liver. Data are expressed as the
mean ± standard deviation (SD). *P < 0.05; **P < 0.01
Fig. 6 Adenovirus-specific IgG responses by immunized group. Each
bar represents the mean ± standard deviation (SD). *P < 0.05; **P < 0.01
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strategy with higher efficacy against S. japonicum, we
designed three types of heterologous prime-boost strategies
in the present study.
DNA and adenoviral vaccines could express the anti-
gen in muscular cells when immunized intramuscularly,
which present protective antigens through the MHC-I
processing pathway and could elicit specific Th1-biased
immune responses [36, 37]. Furthermore, the anti-vector
effect might be minimized using different vaccine deliv-
ery systems (vectors). In the present study, a synergistic
effect was produced by using a DNA i.m. priming-rAdV
i.m. boosting strategy as indicated by an enhancement of
Th1-biased immune responses and protective efficacy
compared to that using DNA i.m. immunization. How-
ever, the observed protective efficacy was similar to that
with rAdV i.m. immunization. This may be due to
differences in vivo transfection efficiency between DNA
plasmids and adenoviruses immunized intramuscularly
because DNA plasmids passively enter cells (penetrate),
whereas adenoviruses enter cells through active infection
(transfection) [36, 37]. This difference may affect the ex-
pression of the delivered antigens and ultimately lead to
differences in specific immune responses and protective
efficacies accordingly.
Replication-deficient adenoviral vectors retain its
actively invading ability to target cells and show high
transfection efficiency when applied to a vaccine delivery
systems [38, 39]. Previous studies have shown that
different types of immune responses and various levels
of protective efficacy are elicited when immunized intra-
muscularly or subcutaneously [26]. To gain a broad
spectrum of specific immune responses, we exploited
rAdV-SjTPI.opt immunized intramuscularly as the prim-
ing vaccine and used different boosting vaccines (rAdV-
SjTPI.opt or rSjTPI, all immunized subcutaneously).
Different outcomes were obtained using these two heter-
ologous prime-boost strategies. A synergistic effect was
produced by the rAdV i.m. priming-rSjTPI boosting
strategy, as indicated by the board spectrum of immune
responses and high protective efficacy (> 70%) against
infection. However, an antagonistic effect was produced
by the rAd i.m. priming-s.c. boosting strategy, as indi-
cated by the moderate levels of immune responses and
protective efficacies. Differences in results may be attrib-
utable to various in the employed vaccines. As earlier
described, adenoviral vectored vaccines immunized
intramuscularly can present antigens via the MHC-I way
and elicit Th1-biased responses. However, protein or
adenoviral vectored vaccines immunized subcutaneously
can present antigens via the MHC-II way and elicit Th2-
biased responses. Anti-vector effects are another group of
factors that affect protective efficacy that is elicited by a
heterologous prime-boost strategy [31, 32, 40]. Through
the detection of specific anti-adenovirus antibodies, the
highest anti-adenovirus antibody levels were observed in
the rAd i.m. priming-s.c. boosting group. These specific
antibodies could efficiently neutralize adenoviral vectored
vaccines as well as cause antagonistic effects on the final
outcomes.
Schistosoma japonicum, a genus of complex multicel-
lular pathogen, undergoes six different developmental
stages, of which the schistosomulum, adult worm, and
egg occur within the definitive host [2]. The specific
immune responses against S. japonicum infection are
complex and have not been clearly elucidated [13].
Previous studies have shown that Th1-biased immune
responses play an important role in protecting against
infections in a radiation-attenuated cercariae animal
model [14, 34]. Furthermore, specific IgG responses may
also contribute to an increase in protective efficacy [35].
In the present study, the rAdV i.m. priming-rSjTPI
boosting strategy elicited broad spectrum immune re-
sponses, which were manifested as higher IgG responses
(IgG levels, IgG titers, and IgG avidity), elevated Th1,
Th2, and Th17 cytokine levels, as well as produced the
highest level of protective efficacy among the three
heterologous prime-boost combinations. These results
were in agreement with those reported in previous
studies.
Conclusion
In summary, we have developed a suitable immunization
strategy, rAdV i.m. priming-rSjTPI boosting strategy,
which elicits a high level of protective efficacy against S.
japonicum infection in mice. However, comparison of dif-
ferent heterologous prime-boost combinations indicated
that different factors may be considered when designing a
suitable heterologous prime-boost strategy, including
types of protective immune responses against infection,
characteristics of different vaccines, anti-vector effects,
and suitable vaccination routes.
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